Leaders from The US Oncology Network and McKesson discuss how technology can enhance precision medicine and improve patient access to cutting-edge cancer treatments.

The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...

Panelists discussed these questions during a recent Institute for Value-Based Medicine® event held in Nashville, Tennessee, ...

Black women living in the most socioeconomically disadvantaged neighborhoods have the highest incidence of TNBC, a national ...

Fox Chase Cancer Center announced the hiring of André Kydd, MD, PhD, as an Assistant Professor in the Department of ...

The 5th Binaytara Precision Oncology Summit, a two-day conference chaired by Dr. Mark Pegram, convenes in San Francisco on October 24-25, 2025. The summit is dedicated to redefining cancer treatment ...

Fox Chase Cancer Center announced the hiring of Saumya Maru, MD, PhD, as an Assistant Professor in the clinical ...

Leading clinicians, researchers & pharmaceutical innovators gathered to discuss the future of cancer treatment.

Robust survivorship care is important because cancer patients have a unique set of medical needs,” said Melissa Erickson, MD.

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio ...

As clinical momentum grows for novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK, this forum delivers a front-row seat ...

More than 35 internationally renowned speakers gathered at the Herbert Park Hotel in Dublin from September 24-26, 2025, for ...